Arbutus biopharma corp (ABUS)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
OPERATING ACTIVITIES
Net Income (Loss) Attributable to Parent

-13,861

-24,654

-82,503

-23,315

-23,251

-18,249

-24,473

3,091

-17,429

-35,931

-11,600

-18,255

-18,627

-218,695

-19,595

-130,000

-15,874

-6,861

-28,982

-14,886

-11,989

-6,168

-8,604

-6,081

-17,984

-2,598

-3,014

-5,905

-2,546

Items not involving cash:
Deferred income tax benefit

-

-

-12,661

-

-

-

-4,282

-

-

-

0

-

-

-

0

-64,864

-

-

-15,196

0

-

-

0

-

-

-

-

-

-

Depreciation

500

-

507

505

509

-

497

578

602

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation

-

-

-

-

-

-

-

-

-

620

593

480

334

332

291

252

217

169

153

147

120

113

133

149

134

147

152

148

166

Gain on sale of property and equipment

0

-31

0

2

9

0

26

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense

1,445

-23

1,516

3,784

1,522

797

1,828

2,661

955

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized foreign exchange losses (gains)

-10

-3

-24

57

38

-208

131

-361

-565

-203

1,328

824

425

-1,126

-826

-51

3,006

5,758

11,790

-2,639

7,057

-

3,245

-1,391

-

42

-3

-15

-6

Warrant issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

0

0

0

-22

191

10

168

161

564

1,976

2,024

-1,223

2,560

-5,140

5,813

-13,616

-1,375

-28

-2,435

308

Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability

100

-79

-376

130

125

-1,035

-5,608

193

-848

213

197

-110

1,059

812

260

252

244

770

0

0

0

-

-

-

-

-

-

-

-

Impairment of Intangible Assets (Excluding Goodwill)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

156,324

-

-

37,990

0

-

-

0

-

-

-

-

-

-

Impairment of intangible assets

-

-

43,836

-

-

-

14,811

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Impairment of goodwill

-

-

22,471

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Site consolidation non-cash portion

-

-

0

0

-

-

0

395

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on investment

-

-

0

0

-

-

0

24,884

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net equity investment gain (loss)

0

-

-3,512

-3,334

-4,651

-

-2,838

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non Cash Royalty Revenue Related To Sale Of Future Royalties

656

-

979

-

171

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense

1,039

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net accretion and amortization of investments in marketable securities

2

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense

-

-

1,106

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts receivable

-132

-1,015

957

608

-777

893

-784

603

317

-589

-196

-6,691

7,605

-122

-61

116

-668

-1,205

-4,047

1,738

2,886

-143

1,852

-1,231

1,409

-3,837

213

2,318

417

Accrued revenue

-

-

0

0

-

-

0

-128

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred lease incentives

-

-

-

-

-

-

-

-

-

-

744

-

-

-

-

-

-

-

-

-

-

-

-

57

-

-

-

-

-

Accrued revenue

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-335

164

-1,304

1,126

411

-39

-220

208

-846

-287

-1,981

1,106

Deferred expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-55

-61

-57

-53

-60

Investment tax credits receivable

-

-

-

-

-

-

-

-

2

326

0

-294

15

145

0

-98

0

-

0

0

-

-

-

-

-

-

-

-10

-

Prepaid expenses and other assets

439

135

-1,080

1,616

-2,277

1,666

-109

-222

-687

643

-83

9

264

-147

-584

573

273

12

-469

519

-221

1,115

383

-243

-482

228

7

47

494

Other assets

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable and accrued liabilities

-3,602

-951

538

888

-2,885

906

1,094

921

-4,187

4,245

-1,805

2,205

-3,909

1,987

-887

42

-1,116

446

2,408

-7,351

2,008

3,788

2,357

-943

1,051

-488

535

-724

807

Deferred revenue

-

-

0

0

-

-649

-325

-746

-1,022

-

-6,739

-653

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent and inducements

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-56

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

7,392

0

-696

-213

-157

-15,144

3,011

334

-1,291

1,233

-806

455

12,289

-742

-734

462

861

Site consolidation accrual

-

-

-138

-640

-

561

-320

61

1,029

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other liabilities

-131

-124

-446

-8

-87

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-15,453

-13,351

-23,470

-17,605

-16,580

-17,073

-13,204

-17,622

-19,967

-10,347

-15,680

-5,078

-17,535

-14,823

-14,712

-16,804

-11,546

-19,341

-2,527

-16,671

-17,843

-6,846

-6,720

-8,010

9,155

2,567

-2,794

-3,670

-2,840

INVESTING ACTIVITIES
Purchase of investments

24,369

-

0

0

334

-

0

0

75,418

-894

-5,843

-1,731

-26,618

-15,906

712

84,439

13,306

630

17,144

9,944

-37,363

-

291

42,992

-

-

-

-

-

Disposition of investments

21,968

-

16,410

10,210

61,389

-

24,590

15,403

0

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash acquired through acquisition

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

324

-

0

0

-

-

-

-

-

Proceeds from sale of property and equipment

0

0

0

2

9

-2

25

2

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Acquisition of property and equipment

0

63

255

240

31

228

237

425

248

182

538

3,121

3,423

2,598

168

954

276

1,174

589

383

141

323

152

246

335

194

210

120

201

Net cash provided by / (used in) investing activities

-2,401

-58,822

16,155

9,972

61,033

32,181

24,378

14,980

-75,666

715

5,305

-1,390

23,195

732

-880

-85,393

-13,582

-1,804

-17,733

-10,327

37,546

1,058

-443

-43,238

-335

-194

-210

-120

-201

Issuance of common shares pursuant to the Open Market Sale agreement

12,315

13,876

0

2,477

2,248

-66,265

0

0

66,265

-

-

-

-

-

-

0

-

0

0

2

142,175

0

0

0

56,477

-

-

-

-

Proceeds from the sale of future royalties

-

-

18,549

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Promissory note repayment

-

-

0

0

-

0

0

0

12,001

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sale of Preferred Shares, net of issuance costs

-

-

0

0

-

-

0

0

-

48,869

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of common shares pursuant to exercise of options

166

17

0

2

288

109

435

735

103

34

61

4

1

0

76

1

115

-24

116

939

620

276

268

148

1,924

278

7

22

82

Issuance of common shares pursuant to exercise of warrants

-

-

-

-

-

-

-

-

-

0

0

0

353

0

0

445

0

-2

0

19

25

193

416

86

888

118

61

54

56

Net cash provided by financing activities

12,481

13,893

18,549

2,479

2,536

109

435

735

54,367

48,903

61

4

354

12,001

76

446

115

-26

116

960

142,820

469

684

234

59,289

32,434

68

76

138

Effect of foreign exchange rate changes on cash and cash equivalents

-10

-

-24

57

38

-

131

-361

-565

-

1,327

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Increase / (decrease) in cash and cash equivalents

-5,383

-

11,210

-5,097

47,027

-

11,740

-2,268

-41,831

-

-8,987

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Effect of foreign exchange rate changes on cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

825

424

-1,127

-824

-51

3,006

6,861

-5,972

967

-2,434

-671

-611

1,924

-2,469

-1,925

-1,454

817

-999

Decrease in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-5,639

6,438

-3,217

-16,340

-101,802

-22,007

-14,310

-26,116

-25,071

160,089

-5,990

-7,090

-49,090

65,640

32,882

-4,390

-2,897

-3,902

Supplemental cash flow information
Fair value of warrants exercised on a cashless basis

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

2,298

-323

-678

107

Non-cash transactions:
Acquired property and equipment in trade payables

-

-

-

-

-

-

-

-

-

-

0

72

1,427

791

266

0

0

-

0

-

-

-

-

-

-

-

-

-

-

Preferred shares dividends accrued

2,978

2,880

2,792

2,762

2,715

2,647

2,567

2,541

2,336

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Initial investment in Genevant

-

-

0

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Fair value of warrants exercised on a cashless basis

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

2,298

-323

-678

107

Fair value of warrants exercised on a cashless basis

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

116

-

-

-

-

-

Investment tax credits received

-

-

-

-

-

-

-

-

-

-

108

108

-

-

0

0

-

-

0

25

-

-

0

0

-

-

-

10

-

Acquisition of Arbutus Inc. net of cash acquired

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

381,618

-

0

0

-

-

-

-

-